Shubh Goel: ADRIATIC Phase III trial for LS-SCLC couldn’t come at a more critical time for patients
Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at
“This post is intended for a US audience:
Today, AstraZeneca announced positive high-level results from the ADRIATIC Phase III trial for limited-stage small-cell lung cancer (LS-SCLC), in patients who had not progressed after concurrent chemoradiotherapy (CRT). Our immunotherapy treatment showed statistically significant and clinically meaningful improvement in overall survival and progression-free survival.
This news couldn’t come at a more critical time for patients: SCLC is a fast-growing, aggressive subtype, making early diagnosis and access to treatment options even more critical to improving survival and quality of life. The standard of care for LS-SCLC hasn’t changed in decades and most patients quickly relapse after CRT. Patients facing this disease have waited far too long for a safe, effective medicine and we’re eager to deliver an innovative therapy that will give them more time. Every new IO discovery means another win on our way to eliminate cancer as a cause of death.
Durvalumab has already been established as a SOC for patients who had not progressed after concurrent chemoradiotherapy with NSCLC, in the PACIFIC study. We are excited to see this data show similar potential for patients with LS-SCLC.
We expect to share the full results at an upcoming medical meeting, but you can read more about today’s announcement here.”
Source: Shubh Goel/LinkedIn